CYTX vs. LNSR, CODX, LUCD, MODD, MDAI, GBS, CTCX, NMTC, DRIO, and FEMY
Should you be buying Cytori Therapeutics stock or one of its competitors? The main competitors of Cytori Therapeutics include LENSAR (LNSR), Co-Diagnostics (CODX), Lucid Diagnostics (LUCD), Modular Medical (MODD), Spectral AI (MDAI), GBS (GBS), Carmell (CTCX), NeuroOne Medical Technologies (NMTC), DarioHealth (DRIO), and Femasys (FEMY). These companies are all part of the "medical" sector.
Cytori Therapeutics (NASDAQ:CYTX) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, community ranking, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.
2.6% of Cytori Therapeutics shares are held by institutional investors. Comparatively, 40.2% of LENSAR shares are held by institutional investors. 0.7% of Cytori Therapeutics shares are held by insiders. Comparatively, 66.0% of LENSAR shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
LENSAR has a net margin of -34.11% compared to Cytori Therapeutics' net margin of -242.60%. LENSAR's return on equity of -40.53% beat Cytori Therapeutics' return on equity.
Cytori Therapeutics has higher earnings, but lower revenue than LENSAR.
Cytori Therapeutics has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500. Comparatively, LENSAR has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500.
In the previous week, Cytori Therapeutics' average media sentiment score of 0.00 equaled LENSAR'saverage media sentiment score.
LENSAR has a consensus price target of $8.00, indicating a potential upside of 166.67%. Given LENSAR's higher possible upside, analysts plainly believe LENSAR is more favorable than Cytori Therapeutics.
Cytori Therapeutics received 437 more outperform votes than LENSAR when rated by MarketBeat users. Likewise, 73.67% of users gave Cytori Therapeutics an outperform vote while only 38.46% of users gave LENSAR an outperform vote.
Summary
LENSAR beats Cytori Therapeutics on 8 of the 13 factors compared between the two stocks.
Get Cytori Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytori Therapeutics Competitors List
Related Companies and Tools
